WHAT IS ALTASCIENCES?
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services.
A MESSAGE FROM OUR CEO
Imagine partnering with an integrated team that you trust, and telling your story once. Imagine a world where everyone and every project is of equal importance. Just imagine…
OUR STORY
For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions.
Our integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements.
Our shared goal: to help you make educated, faster and more complete early phase drug development decisions — to speed you to proof of concept and beyond.
OUR UNIQUE APPROACH
At Altasciences, we provide you with clear, customized roadmaps, supported by our real-time data generation, proprietary communication platform, and central program management and scheduling to help you get to clinical proof of concept, faster.
Our Purpose
Our purpose is to help you research and develop potentially life-saving therapeutics — and get you there faster, with integrated CRO/CDMO services, always moving in unison for maximum efficiency. Our commitment to quality, excellence, integrity, and respect help us deliver big impact with a personal touch.
Our Facilities
1200 Beaumont Avenue
Montreal, QC H3P 3P1
Canada 514 381-2546
Our Origins
OUR EXECUTIVE TEAM
Chris became CEO of Altasciences in 2010. He began his career at Huntingdon Life Sciences in England in 1975 as a toxicologist. He served as Section Head for preclinical development at Beecham Pharmaceuticals, as COO for CTBR Bio-Research in Montreal and then as SVP for Charles River Laboratories, responsible for seven preclinical facilities in the U.S., Canada, and China.
BS in Biology
Cathy joined us in 2010 with the mandate of transforming our commercial offering to cater to the expanding innovator market, and now oversees our commercial strategy, including M&A activity. She started her career at CTBR Bio-Research Inc. (now Charles River Laboratories) and served as Senior Site Director of its Montreal facility.
BA in Psychology, MBA
Dr. Setnik joined Altasciences in 2019. In her previous roles as Vice President of Scientific & Medical Affairs at INC Research/Syneos Health (Early Phase), Senior Director, Clinical Sciences (King Pharmaceuticals and Pfizer, Inc), and Research Scientist (formerly Ventana / Decisionline Clinical Research) she has accumulated impressive experience in early phase clinical trials, regulatory filing, lifecycle management, and strategic initiatives in business development and clinical drug development. Dr. Setnik is also an Adjunct Professor at the University of Toronto, Department of Pharmacology and Toxicology and the Managing Director lead of the Cross Company Abuse Liability Council and chair of the Clinical Pharmacology Community of the Drug Information Association (DIA). She is also an active member and speaker at various congresses including the College on Problems of Drug Dependence; and is actively engaged in many aspects of abuse potential assessment including development of patient reported outcome instruments and contributing to post-marketing surveillance studies.
PhD in Pharmacology and the Collaborative Program in Neuroscience
Dr. Morelli is a member of the College of Physicians of Québec, Canada, with over 30 years' medical experience and over 20 years' global clinical research background. He joined Altasciences in 2013, as a GI consultant and then as Medical Advisor, followed by Clinical PI and now Chief Medical Officer and Executive Vice President Medical Affairs. Prior to joining Altasciences, Dr. Morelli was the Global Medical Director at MDS Pharma for 10 years, overseeing five clinical sites in Canada, the U.S.A., and Ireland. Dr. Morelli is an Associate Professor of Medicine at McGill University Montreal. He also continues to be active staff at the McGill University Hospital Center. In addition, he is Director of Gastroenterology/GI Endoscopy at one of the McGill University affiliated hospitals. He has been lead Principal Investigator in numerous multi-national, multi-center clinical trials.
Steve oversees all of Altasciences' preclinical solutions and sites. He started as a toxicologist for Huntingdon Life Sciences. At CTBR Bio-Research (now Charles River Laboratories) in Montreal, he built the Safety Pharmacology Department, and then moved to China to establish the Charles River Shanghai preclinical facility, which became the first non-clinical facility in China to be certified as OECD GLP compliant. He joined WuXi AppTec in Suzhou, China, as VP of Preclinical Services, before coming to Altasciences in 2014.
BS in Biological Sciences, MS in Toxicology
Marie-Hélène oversees all of Altasciences' clinical and bioanalytical teams, formulation, development and manufacturing capabilities, and research support services, including data management, biostatistics, project management, and medical writing. She started her career as a Business Development Manager at Future Electronics. At Charles River Laboratories, she rose to become Global Director of Marketing, before joining Altasciences in 2012. She was appointed Co-Chief Operating Officer in 2020.
BA in Psychology, Exec MBA
David started his career in 2000 as a Quality Assurance Inspector at CTBR Bio-Research (now Charles River Laboratories). At Pharmascience, he developed and implemented a GxP quality system for both bioanalytical and clinical operations. David has been a member of the Board of Directors of the Canadian Chapter of the Society of Quality Assurance, and served as VP and then President. He joined Altasciences in 2012.
BS in Biology
Julie-Ann joined Altasciences in 2014 to lead business development for our Kansas City site’s operations. In 2016, she was promoted to Vice President, Business Development and in 2017, was appointed to her current position. She began her career in 1998 at Origenix Technologies, a biotech company in Montreal. In 2003, she moved to CTBR Bio-Research (now Charles River Laboratories) where she progressed to Head of Marketing. In 2008, she was seconded to China as Director of Business Development for Charles River Laboratories Shanghai, and then served as Head of Global Marketing for the Charles River Laboratories Preclinical Division. In 2011, she joined WuXi AppTec in Suzhou, China, as Executive Director of Business Development for Preclinical Services, managing staff in China and the U.S.
BS in Exercise Science (Kinesiology), MBA
Robert oversees all of our business development activities. He joined Altasciences in 2012, focusing initially on the growth of our bioanalysis business. Prior, he worked at Charles River Laboratories as a Regulatory Inspector, where he oversaw the Bioanalytical Preclinical segment and managed government audits. He also spearheaded the training and process development programs for the Quality Assurance departments in several site locations. When he joined Altasciences, he transitioned to Business Development, with responsibilities that included key global account oversight.
BS in Physiology, Graduate Diploma in Business Administration
Mariano started his career with Ernst & Young in 1991 before joining Phoenix International as Global Director of Finance where he completed eight acquisitions. Subsequently, he held a number of Chief Financial Officer positions with various companies, including Galileo Genomics, Neurochem, and GFI Solutions. Most recently, Mariano was the Chief Operating Officer and Chief Financial Officer for Klox Technologies. He joined Altasciences in 2018.
B. Commerce, Graduate Degree in Public Accountancy, CPA CA, CPA USA
Consult the detailed biographies of our expert team members, by department
AWARDS
Recognized by the industry, Altasciences has the leadership, scientific, and operational excellence you need to move your programs from lead candidate selection to clinical proof of concept, and beyond.
May 2023
CRO Leadership Awards 2023 (Capabilities)
October 2022
Life Sciences Review Top CRO 2022
May 2022
CRO Leadership Awards 2022 (Multiple Categories)
August 2021
Citeline Awards 2021 Finalist in Best Sponsor-Facing Technology Initiative
June 2019
Pharma Tech Outlook Top 10 CROs
May 2019
Most Successful Early Phase Research (Preclinical and Phase I)
February 2018, 2017, 2016, 2015, 2014
CRO Leadership Awards (Multiple Categories)
August 2018
Pharma Tech Outlook Top 10 CROs
August 2018, 2017, 2016, 2015
PharmaVOICE 100 Most Inspiring Leaders in the Life Sciences Industry - Chris Perkin, CEO
April 2018
Finalist - Most Successful Early Phase Research (Preclinical and Phase I) Clinical and Research Excellence (CARE) Awards by Pharma Intelligence
April 2018
Full-Service Early Stage Clinical Research Provider of the Year Gamechangers™️ Healthcare / Pharmaceutical / Biotech and Medtech Awards 2018
April 2018
Gamechanger of the Year - Chris Perkin, CEO. Gamechangers™️ Healthcare / Pharmaceutical / Biotech and Medtech Awards 2018
January 2018
Best Early Phase CRO in North America Global Health and Pharma (GHP) 2018 Biotechnology Awards
December 2016
Scrip Award for Best CRO - Niche
August 2016
Most Innovative in Biotech TMT News
March 2016
Best Full-Service Early Stage Clinical Research Provider in Canada Global Health and Pharma (GHP) 2016 Biotechnology Awards
October 2015
Annual Canada Awards for Excellence
January 2023
GHP Biotechnology Award for Best Global CRO/CDMO 2023
November 2014
Grands Prix Québécois de la Qualité
OUR CLIENTS
We partner with biotech and pharmaceutical companies of every size and spend, from startups to global leaders. Our client portfolio is deep, international, diverse — and working at the forefront of medical science.
Our People
Altasciences' team (nicknamed the A-Team) is a group of diverse, motivated, and talented people dedicated to excellence, science, and making an impact. Click on the tiles below to get to know some of our team better.
-
Marie-Hélène Raigneau, MBAMarie-Hélène Raigneau, MBAMarie-Hélène has been a leader in the drug development industry for close to 20 years. As COO at Altasciences, she oversees Altasciences' clinical and bioanalytical operations, formulation, development, and manufacturing capabilities, and all CRO support services. -
Dr. Simone Iwabe, DVM, PhD, DACVODr. Simone Iwabe, DVM, PhD, DACVODr. Simone Iwabe is a board-certified veterinary ophthalmologist and specializes in gene therapy, retinal diseases, glaucoma, OCT, ERG, and ocular safety testing. As part of our preclinical team, she's responsible for conducting eye examinations on the research species in our care. Dr. Iwabe also trains technicians on routine tasks. -
Dr. Denise Milovan, PhD, MA, CPsychDr. Denise Milovan, PhD, MA, CPsychNeuroscientist Dr. Denise Milovan is a part of Altasciences' Research Services team, working closely with teams in Business Development, Medical Affairs, Biostatistics, and Clinical Operations to provide science-driven guidance and to promote early adoption of cutting-edge methods to help sponsors reach their milestones. -
Dr. David Nguyen, MD, MBADr. David Nguyen, MD, MBADr. David Nguyen is an anesthesiology-trained General Manager and Medical Director at our Los Angeles clinical facility, with experience in all major inpatient surgical specialties. -
Dr. Gaetano Morelli, MDDr. Gaetano Morelli, MDDr. Morelli joined Altasciences in 2017 as a medical advisor/consultant for complex studies. He quickly transitioned to Clinical Principal Investigator before becoming Chief Medical Officer and Executive Vice President Medical Affairs. -
Dr. Lynne Le Sauteur, PhDDr. Lynne Le Sauteur, PhDDr. Le Sauteur joined Altasciences in September 2019, and leads a team of over 200 scientists involved in bioanalysis, immunogenicity, biomarkers, and immunomodulation assessments for large and small molecules, oligonucleotides, and gene therapy. -
Dr. Anahita Keyhani, PhDDr. Anahita Keyhani, PhDDr. Anahita Keyhani is Altasciences' Senior Director of Scientific Operations, Mass Spectrometry and Method Development. She joined Altasciences in May 2015, and leads a team of over 30 scientists dedicated to regulated bioanalytical method development, validation and sample analysis, from preclinical to Phase IV clinical drug development. -
David GrégoireDavid GrégoireDavid Grégoire joined Altasciences as Director of Quality Assurance in 2012. In 2014, he was appointed Vice President, Quality Systems, with overall responsibility for the QA groups and the implementation of quality systems across the organization. As of 2021, he is now the Chief Quality and Compliance Officer. -
Francis DouvilleFrancis DouvilleFrancis Douville joined the Altasciences team in 2018, as Senior Vice President, Technical Operations, for our preclinical facility in Seattle, Washington. Francis oversees our scientific services, validation and equipment, and training groups, as well as leads the anatomic pathology group. -
Mike BroadhurstMike BroadhurstMike Broadhurst joined the Altasciences’ team in 2018. As the Executive General Manager for our Preclinical Services, Mike works closely with the Altasciences Executive Management Team to ensure quality preclinical services for our clients. -
Ingrid HolmesIngrid HolmesIngrid joined Altasciences in 2011, as Vice President of Global Clinical Operations for our clinical pharmacology units in Montréal, Los Angeles, and Kansas City, which, in total, have over 500 beds.
Social Responsibility
Our people take pride in engaging in the communities where we work and live. Initiatives include Dare to Give breast cancer fundraising, our school supplies campaign, Holiday gift drives for kids, food and winter clothing drives, as well as other ways of giving back. We reflect our passion, commitment, and dedication in everything we do, from our community involvement to our work.
Committed to a sustainable future
Building a healthier future extends beyond the groundbreaking therapies we support. Altasciences is committed to operating sustainably through our comprehensive Environmental, Social, and Governance (ESG) program. We continuously strive to minimize our environmental footprint while championing social responsibility. This dedication is reflected in our participation in the Science Based Targets initiative (SBTi) and the UN Global Compact, solidifying our commitment to a sustainable future.
COMMITMENT TO PARTICIPANTS
We value the people who participate in our clinical trials and contribute to advancing medical science. We, in turn, provide a safe, comfortable, and caring study environment. We treat all our participants respectfully, with transparency and openness, at the initial recruiting and screening process, and throughout the trial period.
FOCUS ON ANIMAL WELFARE
We maintain an unwavering focus on the welfare of the laboratory animals in our care. Our entire preclinical staff is trained in laboratory animal care and focused on animal welfare and environmental enrichment—embracing compassion, sensitivity and adherence to regulatory guidelines.
CEO's Corner
With each quarter comes an opportunity for our CEO, Chris Perkin, to reflect on the past, the present, and the future of Altasciences. Read Chris’ special message to you.
ABOUT US - FAQs
Who owns Altasciences?
Altasciences is owned by Novo Holdings A/S, a world-leading life science investor with a focus on long-term, sustainable value creation. Founded in 1992, Altasciences is a leading, fully-integrated, early drug development solutions platform, providing the pharma and biotech industries with a trusted partner for drug development, from preclinical safety testing through clinical proof-of-concept studies. In the past decade, the company has grown both organically and through acquisitions to have a significant presence in the preclinical safety testing, clinical pharmacology, bioanalytical, CRO services, and CDMO markets. Headquartered in Laval, Canada, Altasciences operates eight facilities in the U.S. and Canada and employs over 1,800 people.
What does Altasciences do?
Altasciences is a contract research organization that offers a flexible approach to early phase drug development. Its integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, formulation, manufacturing and analytical services, program management, medical writing, biostatistics, data management, and more.
What is a CRO?
A contract research organization (CRO) provides support and guidance to pharmaceutical, biotechnology, biopharmaceutical, and medical device companies with the research and development of their products, including generic or novel drugs, in the form of research services outsourced on a contract basis. A CRO is responsible for planning, conducting, and managing contracted research for its clients. At Altasciences, CRO support includes preclinical and clinical research, bioanalysis, formulation, manufacturing and analytical services, medical writing, scientific and regulatory guidance, data management, program management, biostatistics, and more.
What is a CDMO?
A contract development manufacturing organization (CDMO) is a company that supports pharmaceutical, biotechnology, and biopharmaceutical companies with not only the manufacturing of a drug product, but also its development prior to manufacturing. CDMO services are supplied on an outsourced contract basis. At Altasciences, CDMO services include formulation, analysis, method development, clinical supply, and commercial manufacturing.